ENLV Enlivex Therapeutics Ltd.
USHealthcareAs of 2026-07-10 16:00
Why ENLV matters now
Enlivex Therapeutics Ltd. (ENLV) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.86 with -7.30% on the session and $115.5M in market capitalization; recent performance reads 1-month -11.75% and YTD -11.59%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $1.24B, and EPS of $25.79. Investors can compare that operating picture with valuation signals such as P/E 0.02 and FCF yield -73.4%.
The latest indexable market news headline is "Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00; recent insider activity includes Galamidi Einat filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
0.02
PEG
0.00
P/B
0.01
P/S
0.00
EV/EBITDA
-0.96
DCF Value
$-0.04
FCF Yield
-73.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
248.1%
ROA
53.1%
ROIC
-0.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $1.24B | $25.79 |
| FY 2025 | $0.00 | $1.24B | $25.48 |
| Q3 2025 | $0.00 | $-2.2M | $-0.09 |
| Q2 2025 | $0.00 | $-1.9M | $-0.08 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
1.47
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.